NEW YORK (GenomeWeb News) – Metabolon and Bostwick Laboratories today announced an exclusive marketing agreement covering Metabolon's Prostarix test for stratifying prostate cancer risk.

Under the agreement, Bostwick — a full-service laboratory specializing in uropathology, particularly the diagnosis of urological cancers — will market Prostarix for the initial determination of which men may be candidates for prostate biopsy, as well as the determination of which men who have had prior negative biopsies may need repeat biopsies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.